CD274 and non-small cell lung carcinoma: Pembrolizumab has shown survival benefits in the frontline setting for patients with metastatic NSCLC as a single-agent monotherapy and with platinum-based agents in combination therapy, depending on PD-L1 expressions ≥50% and <50%, respectively.